Logo image
Back
Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans
Journal article   Open access   Peer reviewed

Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans

M J Maxwell, S A Messer, R J Hollis, D J Diekema and M A Pfaller
Journal of clinical microbiology, Vol.41(1), pp.97-99
01/2003
DOI: 10.1128/JCM.41.1.97-99.2003
PMCID: PMC149576
PMID: 12517832
url
https://doi.org/10.1128/JCM.41.1.97-99.2003View
Published (Version of record) Open Access

Abstract

The performance of the Etest for voriconazole and amphotericin B susceptibility testing of 162 isolates of Cryptococcus neoformans was assessed against the National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method. The NCCLS method employed RPMI 1640 broth medium, and MICs were read after incubation for 72 h at 35 degrees C. MICs were determined by Etest for all 162 isolates with RPMI 1640 agar containing 2% glucose (RPG agar) and were read after incubation for 72 h at 35 degrees C. The Etest results for both voriconazole and amphotericin B correlated well with reference MICs. Agreement was 94% for voriconazole and 99% for amphotericin B. When discrepancy was noted between the results obtained by Etest and broth microdilution for voriconazole, the Etest generally provided a higher MIC. The Etest method using RPG agar appears to be a useful method for determining the susceptibility of C. neoformans to voriconazole and amphotericin B.
 Antifungal Agents - pharmacology Microbiological Techniques - methods Triazoles - pharmacology Humans Amphotericin B - pharmacology Voriconazole Pyrimidines - pharmacology Microbial Sensitivity Tests - methods Cryptococcus neoformans - drug effects

Details

Metrics

22 Record Views
28 Times Cited - Web of Science
Logo image